Consensus Scholar Rock Holding Corporation

Stocks

SRRK

US80706P1030

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-09-04 EDT			5-day change	1st Jan Change
55.33 ^USD	-1.09%		-2.59%	+25.61%

09-02	Scholar Rock Receives FDA Fast Track Designation For Apitegromab Facioscapulohumeral Muscular Dystrophy Program As Participant Dosing Commences In Phase 2 FORGE Trial	CI
09-02	Scholar Rock Gets FDA Fast Track, Orphan Drug Designations for Muscular Disorder Drug	MT

Evolution of the Average Target: Scholar Rock Holding Corporation

Evolution of the Target Price: Scholar Rock Holding Corporation

Changes in Analyst Recommendations: Scholar Rock Holding Corporation

3f2353d0fe09b2e55b7.UoG5VAz72JCi_AFPxusTmIaIZFdvsoJ44Kn-YPGABmc.KPaOI3y4gqX6zlcO8NNc2uL8XGMC1uoKhJ-kVKbuXCYxzsgsVJKOosSoZg~4809bca3520f07f8eaac7a0ce0df3c9a

Analysts' recommendations: Scholar Rock Holding Corporation

08-21	Wedbush Adjusts Scholar Rock Price Target to $64 From $58, Maintains Outperform Rating	MT
04-21	Canaccord Genuity Initiates Scholar Rock at Buy With $62 Price Target	MT
03-31	Wedbush Adjusts Price Target on Scholar Rock Holding to $58 From $56, Maintains Outperform Rating	MT
03-04	Truist Raises Price Target on Scholar Rock Holding to $55 From $44, Keeps Buy Rating	MT
03-03	Wedbush Adjusts Price Target on Scholar Rock to $56 From $50, Maintains Outperform Rating	MT
01-07	UBS Initiates Scholar Rock Holding at Buy With $60 Price Target	MT
11-14	Wedbush Adjusts Pt on Scholar Rock Holding to $50 From $43, Maintains Outperform Rating	MT
25-09-23	HC Wainwright Adjusts Price Target on Scholar Rock Holding to $44 From $50, Maintains Buy Rating	MT
25-09-23	Scholar Rock's Apitegromab Approval Still Likely Despite Delay, Wedbush Says	MT
25-09-17	Barclays Initiates Scholar Rock at Overweight With $45 Price Target	MT
25-09-15	Leerink Partners Initiates Scholar Rock at Outperform With $51 Price Target	MT
25-08-06	Biopharma Scholar Rock Q2 net loss widens, no revenue	RE
25-07-18	Truist Raises Price Target on Scholar Rock Holding to $54 From $45, Keeps Buy Rating	MT
25-07-17	Cantor Fitzgerald Initiates Coverage on Scholar Rock With Overweight Rating	MT
25-02-27	Wedbush Adjusts Scholar Rock Price Target to $50 From $47, Maintains Outperform Rating	MT
24-11-25	Wedbush Raises Price Target on Scholar Rock to $47 From $40, Maintains Outperform Rating	MT
24-11-25	Truist Securities Adjusts Price Target on Scholar Rock to $45 From $36, Maintains Buy Rating	MT
24-11-12	Wedbush Raises Price Target on Scholar Rock to $40 From $37, Maintains Outperform Rating	MT
24-10-08	Scholar Rock's Spinal Muscular Atrophy Drug Plans for Children Under 2 Could Broaden Patient Group, Truist Says	MT
24-10-07	Scholar Rock's Phase 3 Apitegromab Trial in Spinal Muscular Atrophy Meets Primary Endpoint	MT
24-10-07	Wedbush Raises Price Target on Scholar Rock Holding to $27 From $25, Keeps Outperform Rating	MT
24-10-07	Truist Raises Price Target on Scholar Rock Holding to $36 From $20, Keeps Buy Rating	MT
24-09-27	Wedbush Raises Price Target on Scholar Rock to $25 From $23, Keeps Outperform Rating	MT
24-06-13	BMO Capital Raises Price Target on Scholar Rock to $31 From $29, Maintains Outperform Rating	MT
24-03-28	Raymond James Initiates Scholar Rock With Strong Buy Rating, $30 Price Target	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	SCHOLAR ROCK HOLDING CORPORATION					+9.8%
	WUXI APPTEC CO., LTD.					+21.09%
	ARGENX SE					+11.95%
	INSMED INCORPORATED					+58.51%
	BIONTECH SE					+15.94%
	WUXI BIOLOGICS (CAYMAN) INC.					+16.61%
	GENMAB A/S					+12.11%
	PHARMAESSENTIA CORPORATION					+6.66%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+26.36%
	EXELIXIS, INC.					-9.02%
	Average					+17.00%
	Weighted average by Cap.					+18.72%